AIBioTech Stock

Contract research organization

Sign up today and learn more about AIBioTech Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About AIBioTech Stock

AIBioTech provides drug discovery and diagnostic development organizations a broad range of world-class laboratory services to bring new products to market. Located in a 32,000 square foot laboratory in Richmond, Virginia, AIBioTech is one of the world's most comprehensive Contract Research Organizations in operation. AIBioTech provides reliable expertise and cutting-edge technologies which are not available from other companies. An expert core laboratory, we provide consultation on experimental design and offer comprehensive services under GLP and non-GLP compliance. These services are offered individually or can be integrated to support product development from discovery-to-market with full Regulatory Support under FDA GLP Guidelines 21 CFR 58. AIBioTech provides the following capabilities to clients: Molecular biology Protein expression & analysis and peptide synthesis & purification Bio-analytical services (CLIA certified) Assay development and validation Microbiology, virology & biosafety testing (BSL3 facilities) Program expertise


Executive VP

Thomas R. Reynolds

Director of Biological Chemistries

Russell L. Wolz

Vice President, DNA Services

Gregory Meyers

Director, QA and Regulatory Compliance

Michelle Lilly

President, CSO

Robert B. Harris


David Bostwick

Director, Bioorganic Chemistry

Karen Carter

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: